Pharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches.
|
|
- Judith Reed
- 6 years ago
- Views:
Transcription
1 Pharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches. Lloyd Stevens PhD Senior Research Fellow Pharmaceutical Profiles Nottingham, UK
2 Pharmacokinetic profile driven by extent & rate of both INPUT and OUTPUT functions Elimination Metabolism Excretion Intravenous PK Formulation Absorption Active Transport Gut Metabolism First pass metabolism 22 October
3 Early clinical development: 14 C-based Microdose - IVmicrotracer POmicrotracer/light-label Rapid Manufacturing Under GMP Accelerator Mass Spectrometry Regulatory framework Clinical and logistics know-how 22 October
4 Applications of AMS Candidate selection Human PK profile(s) Metabolite profile SAD design Bioavailability investigation Metabolite profiles/id Elimination (routes, rates) PK modelling Preclinical Phase 0 Further Profiling SAD MAD PoX microdose<100µg API 14 C-dose<270nCi (1µSv) Therapeutic dose light label dosing
5 Microdose PK approach to drug selection Many drug candidates Limited toxicology Screening in vitro in silico etc Promising candidates Animal models Human Microdose Predict behaviour in humans from mathematical models and microdose human in vivo data Wilding and Bell DDT 10 (July 2005) : Select candidate(s) for Phase I
6 Dose extrapolation and pharmacokinetic linearity? Validation for micro to macro dose extrapolation is currently seen as compound specific and is retrospective. Insufficient published industry experience to establish Rules of thumb Time will tell!!. P kinetic micro to macro extrapolation in animals may indicate predictability in man no hard evidence yet.
7 The basic question What are we trying to achieve? Is prediction from micro to macro p kinetics the primary objective in using microdosing? Differentiate between candidate molecules albeit at a microdose level Characterise lead compound Assess other routes Assess metabolism What are the differentiating criteria?
8 PK characteristics relevant to candidate selection/de-selection: Shape EC 50% IC 50% MIC Blood Level of Drug Rapid onset Short duration Migraine Slower onset Long duration Chronic pain 0 24 Time (Hours) Criteria for selection : Dose prediction to achieve??? Onset and duration of action EC 50% & IC 50% or MIC Market driven target product characteristics Dosage regimen Route of administration Drug interaction profile ADME characteristics
9 PK relevant to candidate selection/deselection: Amount & Variability Blood Level of Drug Poor and Variable Bioavailability Subject Time (Hours) Subject 3 Subject 2 Low Bioavailability Blood Level of Drug Short Half Life How much? Low often means.. How Variable? Low may imply extensive metabolism How many & are they active? Measurement of bioavailability relies 0 on IV and Time (Hours) PO crossover 24 study design Good absorption Rapid elimination Short t 1/2 prevents 1x daily dosing
10 Blood Level of Drug PK characteristics relevant to candidate selection/de-selection: Half-life Poor and Variable What s all Bioavailability the fuss about Half-life? Half-life is associated with: 1. Duration of action 2. Time taken to reach steady state In dose extrapolation a doubling Subject of 3 the dose increases the duration Subject 2 of action by only one half-life Subject There is often more Time (Hours) than one halflife. but which is the important one? Potential reasons: Poor permeability? First pass metabolism? Blood Level of Drug Short Half Life 0 24 Time (Hours) Duration of action Good absorption Rapid elimination Short t 1/2 prevents 1x daily dosing
11 Two drugs with the same half-life Ln plasma conc of Drug Pharmacodynamic effect is driven by this section of the P kinetic profile AUC for terminal phase >80% of total AUC Plays a major role in the pharmacodynamic response AUC for terminal phase <20% of total AUC Plays a minor role in the pharmacodynamic response 0 24 Time (Hours)
12 PK characteristics relevant to candidate selection/de-selection: Metabolism Potential metabolic burden as a differentiating factor! M8 Parent dpm/ml plasma M5-M7 M3 M2 M Retention time (h) Xceleron Ltd all rights reserved 2008
13 Candidate selection: Phase 0 Study designs & logistics Design determined by both scientific and commercial objectives IV-oral crossover Absolute absorption and bioavailability Total and renal clearance plus volumes of distribution Oral crossover Concentration vs time profiles (half-life) Limited information on exposure Ideal if target EC 50% is known Subject numbers. Minimum of 4 maximum of 8
14 Microdose data for 5 candidate compounds: IV PK profiles 70 Cl 600 Vss 22 t1/ CL (L/h) Vss (L) t/12 (h) DPH NBI1 NBI2 NBI3 NBI4 0 DPH NBI1 NBI2 NBI3 NBI4 0 DPH NBI1 NBI2 NBI3 NBI4 Courtesy of Neurocrine Biosciences
15 Microdose data for 5 candidate compounds: Oral PK profiles 10 Cmax 10 AUC 1 %F Concentration (ng/ml) AUC (ng.h/ml) 1 Fraction Oral Bioavailability 0.01 DPH NBI1 NBI2 NBI3 NBI4 0.1 DPH NBI1 NBI2 NBI3 NBI4 0.1 DPH NBI1 NBI2 NBI3 NBI4 Courtesy of Neurocrine Biosciences
16 Developability issues arising from a microdose study Concentration (pg/ml) Parent drug IV and oral Total radioactivity IV and oral Metabolite burden Time (hours post-dose) Developability issues Rapid absorption High clearance total 14C LowONO-8539 oral(oral) F total 14C (IV) ONO-8539 (IV) Short half-life (<2h) High metabolic burden Q Metabolism p kinetics/activity
17 Developability issues arising from a microdose study Data suggests systemic metabolism At early time points, total 14 C-to-parent differential was more marked after oral dosing.. indicative of first pass effects ng/ml ng/ml Period 1 Mean 14C Period 1 Mean Parent Hours post-dose Period 2 Mean 14C Period 2 Mean Parent PO IV Hours post-dose ng/ml ng/ml Hours post-dose Hours post-dose
18 AMS applications in early clinical development: Absolute bioavailability Mass balance Metabolite profiling Metabolite identification
19 Applications of AMS Candidate selection Human PK profile(s) Metabolite profile SAD design Bioavailability investigation Metabolite profiles/id Elimination (routes, rates) PK modelling Preclinical Phase 0 Further Profiling SAD MAD PoX microdose<100µg API 14 C-dose<270nCi (1µSv) Therapeutic dose light label dosing
20 Clinical studies to determine the drivers of bioavailability Elimination Metabolism Excretion Formulation Absorption Active Transport Gut Metabolism Intravenous PK Enterion TM
21 Human, IV PK data - earlier than ever before: Why the need for IV PK data? What are the challenges? Experience to date 22 October
22 Why would you want to give an oral NCE by the intravenous route? There is no regulatory requirement to describe the i.v PK for any non-parenteral drug Unless, there is low and variable bioavailability But, there is the potential to gather PK information to enable decision making, such as Total clearance, distribution volumes, absolute bioavailability, potential for biliary excretion, systemic metabolism Assess systemic exposure and absolute bioavailability following vaginal, dermal, ocular, topical, rectal, pulmonary, nasal administration Absolute bioavailability of prodrugs 22 October
23 The Microtracer approach: 14 C-API, AMS + MS IV 14 C-tracer dose given simultaneously at t max with an oral therapeutic/mtd dose in a single period study 1/100 to 1/1000 of oral dose & <270nCi 14 C IV PK for parent drug and metabolites measured using fractionation and AMS Therapeutic oral dose PK measured using LC-MS/MS Piggy-back IV dosing Requires: No supporting animal dosimetry data No in vivo preclinical/clinical tox No IV tolerance test (ICH M3 v2) 0 Time (Hours) 24
24 Identify the causes of variable PK Example: t 1/2 increases with dose Is this due to capacity-limited elimination or poor solubility (flip-flop kinetics)? Blood Level of Drug IV Increasing dose IV/PO crossover will differentiate between non-linear clearance and absorption rate-limited elimination 0 24 Time (Hours)
25 Identify the causes of variable PK Example: wide inter-subject variability Is this due to formulation/dissolution/solubility/permeability or elimination? Blood Level of Drug IV Variability due to output of drug will disappear upon IV dosing 0 24 Time (Hours)
26 IV PK data is essential for predicting in vivo formulation performance 1.6 Simulation 300 Deconvolution Plasma Concentration of RSD1235 (ug/ml) IR Hydrophilic Wax 150 Hydrophilic Actual Wax Actual IR Actual 100 Uptake (mg) Predicted Hydr Actual Hydroph Time (hr) Time (hr) 16 October 2007
27 Human, IV PK data - earlier than ever before: Why the need for IV PK data? What are the challenges? Experience to date 22 October
28 Rapid manufacture of iv doses Changing the Landscape Formulation & Process Development Transfer to GMP Process Development & Verification Stability Study IMPD Submission CT Manufacture & Release Shipping to Clinical Site Off the critical path Dosing Industry standard typically 9-12 months 22 October
29 Human, IV PK data - earlier than ever before: Why the need for IV PK data? What are the challenges? Experience to date 22 October
30 Experience with IV microtracer studies 9 studies to date 2 top 5 pharma 10 biotech/med pharma EU, US, and Jp sponsors IV microtracer Increasing utility and demand Early and late stage development projects Data for inclusion in IND and NDA filing Drug conc n cold drug administered at therapeutic dose 14 C intravenous microdose administered at t max 0 24 Time (hrs) Delivers iv PK profile and absolute bioavailability 22 October
31 Pharmacokinetic profiles for therapeutic oral dose & tracer(1/1000 th ) IV dose Oral dose Coefficient of variation = 48% Concentrationsofradioactivity(ngequivalents/mL) Intravenous dose Coefficient of variation = 21% Time (hours post-dose) t 1/2 F(%) Parameter Sub 1 Sub 2 Sub 3 Sub 4 Sub 5 Sub 6 Sub 7 Sub 8 i.v Oral
32 Study 2: PK profiles for therapeutic oral dose & tracer(1/100 th ) IV dose Plasma conc ng/ml Nominal time (h) 4mg oral Mean Plasma conc ng/ml µg IV Mean Nominal time (h)
33 Study 2: PK profiles for therapeutic oral dose & tracer(1/100 th ) IV dose Plasma conc ng/ml Plasma conc ng/ml LC-MS/MS AMS Nominal time (h) Sensitivity 4mg oral 40µg IV Mean Mean Sensitivity Time scale Nominal time (h)
34 Study 2: PK profiles for therapeutic oral dose & tracer(1/100 th ) IV dose Oral 4mg IV 40µg Lu AA34893, 4 mg Lu AA34893 p.o. ID C max t max AUC 0-24 AUC 0-inf AUC last t ½ CL/F N Mean SD SE Min Median Max CV% Geometric Mean Lu AA34893, 40 µg Lu AA34893 i.v. ID C max AUC 1-25 AUC 0-inf AUC last t ½ CL N Mean SD SE Min Median Max CV% Geometric Mean ID F (AUC0-inf) F (AUC0-24) F (AUClast) N Mean SD SE Min Median Max CV% Geometric Mean
35 Flexible and integrated protocols: Cost effective generation of critical data Single ascending dose protocol +/- Food Age/gender Dose1 Dose2 Dose3 Dose..n Metabolite ID AbsBio/IV PK Formulation/BA Single Ascending Dose Optional Leg Protocol is specific to the study and tailored to the scientific questions of the project
36 Changing Early Development model Flexible/ integrated SAD/MAD protocols Absolute Bioavailability (oral MTD+ 14 C i.v tracerdose) Single Ascending Dose Traditional Development Multiple Ascending Dose Metabolite Identification (oral light label 14 C MTD)
37 Conclusions AMS: Key role in compound characterisation and early clinical development Microdosing/Phase 0 has proven utility to select compounds based on their human p kinetic characteristics IV-PK data adds value to understanding drivers of poor and variable bioavailability, plus IV PK modelling (IVIVC) IV-Microtracer TM underpinned by rapid GMP manufacture Regulatory acceptance for methods employed and validity in the derived results is established
38 Thank you
39 Coordination of key service providers Pharmaceutical Profiles Project management, ethics, regulatory approvals and clinical conduct Pharmacokinetic analyses Data management Xceleron AMS LC-MS/MS Plasma, urine & feces concentrations and metabolite identification Sponsor 14 C-IMP supplies GLP,GCP,GMP auditing Pharmacovigilance
40 Sample Flow Samples generated at PP 1. AMS provider total and parent 14 C analysis X ml plasma (n = 26 samples 6 volunteers) 2. AMS provider Total 14 C analysis X ml whole blood (n = X samples 6 volunteers) 3. AMS provider analysis (metabolites) X ml urine (n = X pooled samples) 4. AMS provider analysis (metabolites) Faecal samples (n = X pooled samples) 5. Bioanalysis X ml plasma (n = 26 samples 6 volunteers) Extraction of X ml plasma samples 6. AMS provider Metabolite profiling (n = X pooled samples) Remaining extraction Metabolite ID (n = X Samples)
Absolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches.
Absolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches. Dr Lloyd Stevens Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationTracer studies in GSK for Discovery and Development
Tracer studies in GSK for Discovery and Development 3 rd June 2010...a ripple or a wavefront? Graeme Young, DMPK, GlaxoSmithKline R&D, Ware, UK Outline Historical use of AMS at GSK variety of ADME studies;
More informationUsing Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop
Using Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop Topics to be Addressed Why AMS? AMS for mass balance studies with vismodegib AMS for absolute bioavailability
More informationHuman ADME Study Design Considerations in Healthy Subjects and in Patients
Human ADME Study Design Considerations in Healthy Subjects and in Patients Daria Stypinski BSc (Pharm), PhD Clinical Pharmacology Sciences Nov 18, 2015 Learning Goals and Outline What is a human ADME study?
More informationDMPK. APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology
DMPK APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology What I learned is a good DMPK profile have acceptable water solubility for development be completely absorbed, preferably via
More informationAMS: A smarter way to cut through the MIST. Bob Ings RMI-Pharmacokinetics
AMS: A smarter way to cut through the MIST Bob Ings RMI-Pharmacokinetics www.rmi-pharmacokinetics.com Objectives Brief overview of Accelerator Mass Spectrometry (AMS) and its history Reminder of the MIST
More informationA novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of simeprevir in healthy volunteers
A novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of simeprevir in healthy volunteers Sivi Ouwerkerk-Mahadevan, 1 Jan Snoeys, 1 Alex Simion,
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationBasic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations
Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations Rosenbaum, Sara E. ISBN-13: 9780470569061 Table of Contents 1 Introduction to Pharmacokinetics and Pharmacodynamics.
More informationNOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3A
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT
More informationOral Soluble Film Products for Epilepsy: Clobazam (COSF) and Diazepam (DBSF)
Oral Soluble Film Products for Epilepsy: Clobazam (COSF) and Diazepam (DBSF) Michael A. Rogawski, M.D., Ph.D. Professor of Neurology and Pharmacology School of Medicine University of California, Davis
More informationFDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES
FDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES 1 SCOPE In pursuance of section 47 of the Food and Drugs Law 1992, P.N.D.C.L 305B, as amended by Act 523, 1996, these
More information1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?
Page 1 PHAR 750: Biopharmaceutics/Pharmacokinetics October 23, 2009 - Form 1 Name: Total 100 points Please choose the BEST answer of those provided. For numerical answers, choose none of the above if your
More informationBIOPHARMACEUTICS and CLINICAL PHARMACY
11 years papers covered BIOPHARMACEUTICS and CLINICAL PHARMACY IV B.Pharm II Semester, Andhra University Topics: Absorption Distribution Protein binding Metabolism Excretion Bioavailability Drug Interactions
More information3/31/2009. Phase 0 Microdosing Studies with Renin Inhibitors. Disclaimer. Overview of Today s Presentation. J. Chris Jensen Consultant
Phase 0 Microdosing Studies with Renin Inhibitors J. Chris Jensen Consultant Speedel Holding Ltd. Basel, Switzerland Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationApplication of IVIVCs in Formulation Development Douglas F Smith
Application of IVIVCs in Formulation Development Douglas F Smith PQRI Workshop on Application of IVIVC in Formulation Development September 5-6, 2012 Bethesda, Maryland In Vitro/In Vivo Correlations -
More informationThe Opportunity: c-ibs and pain relief with confidence YKP10811
The Opportunity: c-ibs and pain relief with confidence YKP10811 1 TABLE OF CONTENTS Profile Summary Clinical Data Mode of Action Pharmacologic Profile Safety and Toxicity Profile ADME Overview vs. Competitors
More informationGeneral Principles of Pharmacology and Toxicology
General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University
More informationIs a Maximal Tolerated Dose in Human useful for drug development?
Is a Maximal Tolerated Dose in Human useful for drug development? How to define an acceptable highest dose to be tested? EuFeMED, London Pre-conference Workshop 17-May-2017 Eric Legangneux Philippe Grosjean
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationPublic Assessment Report. Scientific discussion. Ropinirol Actavis. Ropinirole hydrochloride DK/H/1212/ /DC
Public Assessment Report Scientific discussion Ropinirol Actavis Ropinirole hydrochloride DK/H/1212/001-007/DC This module reflects the scientific discussion for the approval of Ropinirole film-coated
More informationDE/H/0763/01-04 / MR DE/H/0764/01-04 / MR DE/H/0765/01-05 / MR
PUBLIC ASSESSMENT REPORT Mutual Recognition Procedure Module 5 Scientific discussion during the initial procedure Fenta Regiomedica Matrix 25 / 50 / 75 and 100 µg/h transdermal patch Fentapatch Matrix
More informationConflict of Interest Statement
Specific Aspects and Approaches for Regulatory Evaluation of Pharmaceuticals in Two-Year Rodent Carcinogenicity Studies James A. Popp Stratoxon LLC Morgantown, PA Tel: 610.286.7592 popp@stratoxon.com Conflict
More informationBiomath M263 Clinical Pharmacology
Training Program in Translational Science Biomath M263 Clinical Pharmacology Spring 2013 www.ctsi.ucla.edu/education/training/webcasts Wednesdays 3 PM room 17-187 CHS 4/3/2013 Pharmacokinetics and Pharmacodynamics
More informationPrinciples of Toxicokinetics/Toxicodynanics
Biochemical and Molecular Toxicology ENVR 442; TOXC 442; BIOC 442 Principles of Toxicokinetics/Toxicodynanics Kim L.R. Brouwer, PharmD, PhD kbrouwer@unc.edu; 919-962-7030 Pharmacokinetics/ Toxicokinetics:
More informationDevelopment of Canagliflozin: Mechanistic Absorption Modeling During Late-Stage Formulation and Process Optimization
Development of Canagliflozin: Mechanistic Absorption Modeling During Late-Stage Formulation and Process Optimization Nico Holmstock Scientist, Janssen R&D M CERSI 2017, BALTIMORE (USA) Canagliflozin An
More informationIPAC-RS/UF Orlando Inhalation Conference March 20, S.T. Horhota 1, C.B. Verkleij 2, P.J.G. Cornelissen 2, L. Bour 3, A. Sharma 3, M.
IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Case Study: Pharmacokinetics and Pharmacodynamics of Tiotropium and Salmeterol Following Parallel Administration in COPD Patients Using Different
More informationPharmacokinetic Modeling & Simulation in Discovery and non-clinical Development
Pharmacokinetic Modeling & Simulation in Discovery and non-clinical Development Where do we stand? Disclaimer I am not a bioinformatician, mathematician or biomedical engineer. I am a simple minded pharmacist,
More informationCurrent Challenges and Opportunities in Demonstrating Bioequivalence
Current Challenges and Opportunities in Demonstrating Bioequivalence Gur Jai Pal Singh, Ph.D. Watson Laboratories, Inc. Corona, California, USA Demonstrating Bioequivalence of Locally Acting Orally Inhaled
More informationExploiting BDDCS and the Role of Transporters
Exploiting BDDCS and the Role of Transporters (Therapeutic benefit of scientific knowledge of biological transporters, understanding the clinical relevant effects of active transport on oral drug absorption)
More informationSupplementary Table 1: Summary of 33 Patients Treated with Abemaciclib in Dose Escalation
Supplementary Table 1: Summary of 33 Patients Treated with Abemaciclib in Dose Escalation Cohort Dose and Frequency Age and Sex Tumor Type Number of Cycles Best Overall Response 4M Colorectal cancer -
More informationAdaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient
Adaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient Michelle L. Combs, PhD Vice President, Clinical Pharmacology Sciences New Drug And Biologics
More information1 Introduction: The Why and How of Drug Bioavailability Research
j1 1 Introduction: The Why and How of Drug Bioavailability Research Han van de Waterbeemd and Bernard Testa Abbreviations ADME EMEA FDA NCE PD P-gp PK R&D Absorption, distribution, metabolism, and excretion
More informationTCP Transl Clin Pharmacol
TCP 2015;23(1):26-30 http://dx.doi.org/10.12793/tcp.2015.23.1.26 Bioequivalence study of Donepezil hydrochloride in healthy Korean volunteers ORIGINAL ARTICLE Yewon Choi 1, Su-jin Rhee 1, In-Jin Jang 1,
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationUSING PBPK MODELING TO SIMULATE THE DISPOSITION OF CANAGLIFLOZIN
USING PBPK MODELING TO SIMULATE THE DISPOSITION OF CANAGLIFLOZIN Christophe Tistaert PDMS Pharmaceutical Sciences Preformulation & Biopharmaceutics AAPS 2015, FLORIDA (USA) Canagliflozin An orally active
More informationDr. M.Mothilal Assistant professor
Dr. M.Mothilal Assistant professor Bioavailability is a measurement of the rate and extent of drug that reaches the systemic circulation from a drug product or a dosage form. There are two different types
More informationHelmut Schütz. The Global Bioequivalence Harmonisation Initiative. 12 April 2018 [Session II: Necessity of multiple dose studies in BE testing] 1
Primary and secondary PK metrics for evaluation of steady state studies, C min vs.c τ, relevance of C min /C τ or fluctuation for bioequivalence assessment Helmut Schütz 12 April 2018 [Session II: Necessity
More informationIntroduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Introduction to 1 Pharmacokinetics University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 2 Learning objectives Understand compartment models and how they effects
More informationMetformin: Mechanistic Absorption Modeling and IVIVC Development
Metformin: Mechanistic Absorption Modeling and IVIVC Development Maziar Kakhi *, Ph.D. FDA Silver Spring, MD 20993 Maziar.kakhi@fda.hhs.gov Viera Lukacova, Ph.D. Simulations Plus Lancaster, CA 93534 viera@simulations-plus.com
More informationSponsor / Company: Sanofi Drug substance: SAR236553/REGN727 (alirocumab)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance:
More informationAGRICULTURAL CHEMICAL SAFETY ASSESSMENT (ACSA)
HESI ILSI Health and Environmental Sciences Institute AGRICULTURAL CHEMICAL SAFETY ASSESSMENT (ACSA) ADME Task Force Hugh A. Barton, PhD National Center for Computational Toxicology Office of Research
More informationDOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *)
DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *) Guideline Title Dose Selection for Carcinogenicity Studies of Pharmaceuticals *) Legislative basis Directive 75/318/EEC as amended Date
More informationClick to edit Master title style
A Short Course in Pharmacokinetics Chris Town Research Pharmacokinetics Outline Pharmacokinetics - Definition Ideal Pharmacokinetic Parameters of a New Drug How do we optimize PK for new compounds Why
More informationPractical Application of PBPK in Neonates and Infants, Including Case Studies
Practical Application of PBPK in Neonates and Infants, Including Case Studies Presented at the conference : Innovative Approaches to Pediatric Drug Development and Pediatric Medical Countermeasures: A
More informationSYNOPSIS. The study results and synopsis are supplied for informational purposes only.
SYNOPSIS INN : LEFLUNOMIDE Study number : HMR486/1037 et HMR486/3503 Study title : Population pharmacokinetics of A77 1726 (M1) after oral administration of leflunomide in pediatric subjects with polyarticular
More informationSponsor: Sanofi Drug substance(s): SAR342434
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationEMA/EGA. Session 1: orally administered Modified Release Products European Regulatory Requirements London 30 April 2015 Dr.
EMA/EGA Session 1: orally administered Modified Release Products European Regulatory Requirements London 30 April 2015 Dr. Henrike Potthast Disclaimer The presentation reflects the personal opinion of
More informationPharmacokinetics of strong opioids. Susan Addie Specialist palliative care pharmacist
Pharmacokinetics of strong opioids Susan Addie Specialist palliative care pharmacist What is the difference between pharmacokinetics and pharmacodynamics? Definitions Pharmacokinetics = what the body does
More informationMultiple IV Bolus Dose Administration
PHARMACOKINETICS Multiple IV Bolus Dose Administration ١ Multiple IV Bolus Dose Administration Objectives: 1) To understand drug accumulation after repeated dose administration 2) To recognize and use
More informationFinal Report (Amendment 1) April 11, 2006 Page 4 of 50
Page 4 of 50 2 SYNOPSIS Title: A Bioavailability Study to Assess the Bioequivalence of Alfacalcidol Capsule and Oral Drop Formulations: A Comparative, Randomized, Single-Dose, 4-Way Crossover Bioavailability
More informationPrincipal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA
SYNOPSIS Issue Date: 06 October 2008 Document No.: EDMS-PSDB-8954363:2. Name of Sponsor/Company Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Name of Finished Product Name of Active Ingredient(s)
More informationSCIENTIFIC DISCUSSION. Antimycobacterial (J04AC01).
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): International Nonproprietary Name: Pharmaco-therapeutic
More informationPreclinical Requirements for Therapeutic Studies in Humans with Advanced Cancer
Preclinical Requirements for Therapeutic Studies in Humans with Advanced Cancer Scott Laurie MD, FRCPC The Ottawa Hospital Cancer Centre Associate Professor, University of Ottawa Disclosures I have no
More informationYear in review. Vit Perlik Director of Regulatory Science and Clinical Development
Year in review Vit Perlik Director of Regulatory Science and Clinical Development Content Year in review Covering September 2013 to September 2014 Where the regulation goes selection of events for illustration
More informationModeling & Simulation to support evaluation of Safety and Efficacy of Drugs in Older Patients
Modeling & Simulation to support evaluation of Safety and Efficacy of Drugs in Older Patients Eva Bredberg, Director Global Clinical Pharmacology, AstraZeneca On behalf of EFPIA EMA Geriatrics Workshop
More informationBiopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application
Biopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application Leslie Z. Benet, Ph.D. Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine
More informationPublic Assessment Report. Scientific discussion. Metoprololsuccinat Actavis. Prolonged release tablets 25 mg, 50 mg, 100 mg and 200 mg
Public Assessment Report Scientific discussion Metoprololsuccinat Actavis Prolonged release tablets 25 mg, 50 mg, 100 mg and 200 mg Metoprolol succinate This module reflects the scientific discussion for
More informationClinical Trials A Practical Guide to Design, Analysis, and Reporting
Clinical Trials A Practical Guide to Design, Analysis, and Reporting Duolao Wang, PhD Ameet Bakhai, MBBS, MRCP Statistician Cardiologist Clinical Trials A Practical Guide to Design, Analysis, and Reporting
More informationPHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 FINAL EXAM FALL 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /14 pts 2. /10 pts 3. /8 pts 4 /8 pts 5. /12 pts 6. /8 pts
More informationPUBLIC ASSESSMENT REPORT Scientific Discussion
Direction de l Evaluation des Médicaments et des Produits Biologiques PUBLIC ASSESSMENT REPORT Scientific Discussion Tramadol hydrochloride + paracetamol 37.5 mg-325 mg Grünenthal film coated tablets Bonoc
More informationPublic Assessment Report Scientific discussion. Anastrozole Bluefish 1 mg film-coated tablets (anastrozole) SE/H/781/01/DC
Public Assessment Report Scientific discussion Anastrozole Bluefish 1 mg film-coated tablets (anastrozole) SE/H/781/01/DC This module reflects the scientific discussion for the approval of Anastrozole
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationSYNOPSIS. Number of subjects: Planned: 22 Randomized: 23 Treated: 23. Evaluated: Pharmacodynamic: 22 Safety: 23 Pharmacokinetics: 22
SYNOPSIS Title of the study: A randomized, cross-over, open, euglycemic clamp study on the relative bioavailability and activity of 0.6 U/kg insulin glargine and 20 µg lixisenatide, given as on-site mix
More informationIntroduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017
Introduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017 1 Outline Definition & Relevance of Pharmacokinetics
More informationPharmacokinetics I. Dr. M.Mothilal Assistant professor
Pharmacokinetics I Dr. M.Mothilal Assistant professor DRUG TRANSPORT For a drug to produce a therapeutic effect, it must reach to its target and it must accumulate at that site to reach to the minimum
More informationJ Clin Pharm OnlineFirst, published on September 23, 2009 as doi: /
J Clin Pharm OnlineFirst, published on September 23, 2009 as doi:.1177/0091270009343698 Microdose Pharmacokinetics of and, Candidate HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors, Following Oral
More informationNoncompartmental Analysis (NCA) in PK, PK-based Design
Noncompartmental Analysis (NCA) in PK, PK-based Design Helmut Schütz BEBAC Consultancy Services for Bioequivalence and Bioavailability Studies 17 Vienna, Austria helmut.schuetz@bebac.at Bioequivalence
More informationTo assess safety profiles: significant laboratory changes and adverse events (AEs).
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationDRAFT GUIDANCE DOCUMENT Comparative Bioavailability Standards: Formulations Used for Systemic Effects
1 2 3 DRAFT GUIDANCE DOCUMENT Comparative Bioavailability Standards: Formulations Used for Systemic Effects 4 This guidance document is being distributed for comment purposes only. 5 6 Published by authority
More informationAssessing the role of hepatic uptake in drug clearance - Pharmacokinetic and experimental considerations
Assessing the role of hepatic uptake in drug clearance - Pharmacokinetic and experimental considerations Peter Webborn ISSX Short course Toronto 2013 1 Defining the why, when and how of Transporter studies
More informationUNIVERSITY OF THE WEST INDIES, ST AUGUSTINE
UNIVERSITY OF THE WEST INDIES, ST AUGUSTINE FACULTY OF MEDICAL SCIENCES SCHOOL OF PHARMACY BACHELOR OF SCIENCE IN PHARMACY DEGREE COURSE SYLLABUS COURSE TITLE: COURSE CODE: BIOPHARMACEUTICS, NEW DRUG DELIVERY
More informationAPX001 A novel broad spectrum antifungal agent in development for the treatment of invasive fungal infections
APX001 A novel broad spectrum antifungal agent in development for the treatment of invasive fungal infections TIMM, Belgrade, Serbia October, 2017 New antifungal drugs in the pipeline S15 Dr. Michael Hodges
More informationRenal Impairment From Dettli to Guideline: What can we learn?
Renal Impairment From Dettli to Guideline: What can we learn? SocraMetrics GmbH Mainzerhofplatz 14 99084 Erfurt phone: ++49-361-6020526 fax: ++49-361-6020525 e-mail: meinolf.wonnemann@socrametrics.de SocraMetrics
More informationPK/PD analysis in assessment of abuse deterrence
PK/PD analysis in assessment of abuse deterrence Megan J. Shram, PhD Director and Principal, Altreos Research Partners Inc. Adjunct Professor and Lecturer, Department of Pharmacology, University of Toronto
More informationStrategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population
Strategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population Nina Isoherranen Department of Pharmaceutics University of Washington Processes driving drug disposition are
More informationInterchangeable Drug Products - Additional Criteria
Interchangeable Drug Products - Additional Criteria Principle: Decisions respecting interchangeability and drug lists remain in the domain of the institution responsible for the costs of the product which
More informationDr. Nele Plock. Dr. N. Plock, March 11, 2008, American Conference on Pharmacometrics
Parallel PKPD modeling of an endogenous agonist (A) and exogenous antagonist (B) based on research PKPD data to predict an effective first-in-man dose of B A combination of physiologically based PK and
More informationPopulation pharmacokinetics of bedaquiline (TMC207) and its M2 and M3 metabolites with efavirenz demonstrate reduced exposure
Population pharmacokinetics of bedaquiline (TMC207) and its M2 and M3 metabolites with efavirenz demonstrate reduced exposure Elin M Svensson 1 Kelly E Dooley 2, Francesca Aweeka 3, Jeong-Gun Park 4, Mats
More informationSponsor: Sanofi Drug substance(s): GZ316455
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationRevised European Guideline on PK and Clinical Evaluation of Modified Release Dosage Forms
1st MENA Regulatory Conference on Bioequivalence, Biowaivers, Bioanalysis and Dissolution Jordan September 23 24, 2013 Revised European Guideline on PK and Clinical Evaluation of Modified Release Dosage
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationRisk and Benefit Assessments for Optimal Dose Selection Based on Exposure Response
Risk and Benefit Assessments for Optimal Dose Selection Based on Exposure Response 2003 FDA/Industry Statistics Workshop Peter I. Lee, PhD Associate Director, Pharmacometrics OCPB, CDER, FDA Disclaimers
More informationAssay Cross Validation
Assay Cross Validation Recent experiences in transferring bioanalytical assays from sponsor to CRO partners and between CROs Stephen White EBF Open Symposium Barcelona 20 th Nov 2013 Assay Cross Validation
More informationSafety, PK and PD of ARRY-502, a CRTh2 Antagonist, in Healthy Subjects with a History of Seasonal Allergies
Safety, PK and PD of ARRY502, a CRTh2 Antagonist, in Healthy Subjects with a History of Seasonal Allergies L. Burgess*, L. Anderson, C. Nugent, N. Klopfenstein, C. Eberhardt, L. Carter, C. Kass, S. RojasCaro,
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion Cabergoline Sandoz (cabergoline) SE/H/899/01-03/DC This module reflects the scientific discussion for the approval of Cabergoline Sandoz. The procedure was
More informationPharmacokinetic parameters: Halflife
Pharmacokinetic parameters: Halflife (t 1/2 ) 1. By definition t 1/2 is the time required for the concentration to fall by one half. For drugs with first order kinetics this is a constant. 2. Half-life
More informationPharmacokinetics in Drug Development. Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core
Pharmacokinetics in Drug Development Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core Finding new drugs: A crap shoot Clinical Development Phase
More informationPHA Spring First Exam. 8 Aminoglycosides (5 points)
PHA 5128 Spring 2012 First Exam 1 Aminoglycosides (5 points) 2 Aminoglycosides (10 points) 3 Basic Principles (5 points) 4 Basic Principles (5 points) 5 Bioavailability (5 points) 6 Vancomycin (5 points)
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationVolume 1(3) May-June 2013 Page 351
ISSN: 2321-5674(Print) BIOAVAILABILITY: CRITERIA FOR APPROVING A DRUG PRODUCT FOR MARKETING Sandhya Singh 1, Faheem Ajmal Ansari 1, Shravan Paswan 2*, Rnjan Kumar Sharma 2, Alok Ranjan Gaur 3 1 Azad Institute
More informationThe Comet Assay Tails of the (Un)expected
The Comet Assay Tails of the (Un)expected Use of the in vivo comet assay in pharmaceutical development Bas-jan van der Leede Janssen R&D Johnson & Johnson Pharmaceutical Companies Discovery Sciences Genetic
More informationDrug development of highly potent therapeutic peptides Regulated microdose Bioanalysis
Drug development of highly potent therapeutic peptides Regulated microdose Bioanalysis Magnus Knutsson, Director, Bioanalysis LC-MS/MS Ferring Pharmaceuticals A/S Copenhagen, Denmark Presented at EBF Open
More informationThe use of Saliva instead of Plasma as a Surrogate in Drug Bioavailability and Bioequivalence Studies in Humans
The use of Saliva instead of Plasma as a Surrogate in Drug Bioavailability and Bioequivalence Studies in Humans ا.د. ناصر محمد ياسر نمرادكيدك Prof. Nasir M. Idkaidek University of Petra Amman - Jordan
More informationPhase I in clinical drug development
Phase I in clinical drug development M2 Pharmacocinétique 31 janvier 2013 Philippe Grosjean Sanofi R&D Clinical Sciences and Operations 1 New drug investigations in human Objectives of the clinical investigations
More informationPharmaceutics I صيدالنيات 1. Unit 2 Route of Drug Administration
Pharmaceutics I صيدالنيات 1 Unit 2 Route of Drug Administration 1 Routs of Drug administration The possible routes of drug entry into the body may be divided into two classes: Parenteral Rout Enteral Rout
More informationIndustry Experience of the Concentration-QTc Relationship in Phase 1 Studies. Corina Dota, AstraZeneca
Industry Experience of the Concentration-QTc Relationship in Phase 1 Studies Corina Dota, AstraZeneca CSRC-2 th February 2012 ICH E14 2.2.5 Alternative Strategies to Assess QT/QTc Interval Effects Alternatives
More informationVarun Goel 1, Nathalie H Gosselin 2, Claudia Jomphe 2, Husain Attarwala 1, Xiaoping (Amy) Zhang 1, JF Marier 2, Gabriel Robbie 1
Population Pharmacokinetic (PK) / Pharmacodynamic (PD) Model of Serum Transthyretin (TTR) Following Patisiran Administration in Healthy Volunteers and Patients with Hereditary TTR-Mediated (hattr) Amyloidosis
More information